Sartorius Stedim Biotech SA
DIM
Company Profile
Business description
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
Contact
Otto-Brenner-Strasse 20
Goettingen37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
10,265
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.20 | 12.20 | -0.14% |
| CAC 40 | 8,141.92 | 15.90 | -0.19% |
| DAX 40 | 24,083.53 | 45.45 | -0.19% |
| Dow JONES (US) | 49,167.79 | 62.92 | -0.13% |
| FTSE 100 | 10,321.09 | 57.99 | -0.56% |
| HKSE | 25,755.72 | 169.93 | -0.66% |
| NASDAQ | 24,887.10 | 50.50 | 0.20% |
| Nikkei 225 | 60,238.21 | 299.15 | -0.49% |
| NZX 50 Index | 12,766.99 | 107.95 | -0.84% |
| S&P 500 | 7,173.91 | 8.83 | 0.12% |
| S&P/ASX 200 | 8,712.40 | 8.80 | -0.10% |
| SSE Composite Index | 4,076.91 | 9.43 | -0.23% |